IMD-1743 / Affinity Biopharma - LARVOL DELTA

Tumor microenvironment-activated T-cell engager (TMEA-TCE) targeting claudin 6 demonstrates efficacy without inducing cytokine release syndrome (AACR 2026) - "This activation strategy follows the same proof-of-concept demonstrated by the successful phase 3 studies of legubicin, an albumin-drug conjugate (ALDC). Pharmacokinetic studies in cynomolgus monkeys revealed high concentrations of IMD-1743 and minimal free TCE, indicating that the molecule is highly stable in circulation.In summary, these findings highlight a favorable therapeutic margin for IMD-1743 as a safe and effective TCE candidate targeting claudin 6. The strong preclinical efficacy combined with its tolerability profile supports further clinical development of IMD-1743 to address the significant unmet medical needs of patients with CLDN6-expressing tumors."

Biomarker • Clinical • Cytokine release syndrome • Tumor microenvironment • Gastric Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CLDN4 • CLDN6 • LGMN